Improved survival time trends in Hodgkin's lymphoma
Authors:
Open Access
- 21 March 2016
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 5 (6) , 997-1003
Abstract
There have been dramatic changes in the staging and treatment of Hodgkin's lymphoma (HL) over the past 30 years. We undertook this study to determine if a stage migration had occurred and also examined if treatment associated with later years has improved survival. Patients with stage I-IV HL between 1983 and 2011 were selected from the Surveillance, Epidemiology, and End Results database. Multivariable analysis (MVA) was performed using Cox proportional hazards modeling. The study cohort included 35,680 patients. The stage breakdown in 1983 according to A and B symptoms was follows: 18%, 21%, 12%, and 5% for stage IA, IIA, IIIA, and IVA disease, respectively, and 6%, 11%, 12%, and 15% for stage IB, IIB, IIIB, and IVB disease. The stage breakdown in 2011 according to A and B symptoms was follows: 9%, 29%, 10%, and 6% for stage IA, IIA, IIIA, and IVA disease, respectively, and 4%, 16%, 12%, and 13% for stage IB, IIB, IIIB, and IVB disease. The median follow-up for the entire cohort is 6.1 years. On MVA, the HR for mortality of patients diagnosed in 2006 was 0.60 (95% Confidence Interval (CI): 0.52–0.70) compared to 1983. For stage I and II patients diagnosed in 2006 the HR was 0.62 (95% CI: 0.44–0.87) and 0.40 (95% CI: 0.30–0.55), respectively, compared to patients diagnosed in 1983. For stage III and IV patients diagnosed in 2006 the HR was 0.72 (95% CI: 0.53–0.98) and 0.74 (95% CI: 0.56–0.99), respectively, compared to patients diagnosed in 1983. This is the first study to demonstrate a significant stage migration in early stage Hodgkin's lymphoma. Furthermore, these results demonstrate an improvement in survival over time for patients with Hodgkin's lymphoma which was particularly notable for those with early stage disease.Keywords
Funding Information
- Bucksbaum Institute for Clinical Excellence
This publication has 27 references indexed in Scilit:
- Should Cause of Death From the Death Certificate Be Used to Examine Cancer-Specific Survival? A Study of Patients With Distant Stage DiseaseCancer Investigation, 2010
- Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patientsBlood, 2008
- Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 TrialJournal of Clinical Oncology, 2007
- The role of FDG PET in the management of lymphoma: what is the evidence base?Nuclear Medicine Communications, 2007
- Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's LymphomaJournal of Clinical Oncology, 2007
- Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trialsAnnals of Oncology, 2006
- Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled TrialsJournal of Clinical Oncology, 2006
- Management of Hodgkin LymphomaMayo Clinic Proceedings, 2006
- Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's diseaseAnnals of Oncology, 2004
- Improved survival in Hodgkin's diseaseCancer, 1976